Our pipeline
We have an exciting and balanced pipeline underpinned by great science.
Home / Our therapy areas / Our pipeline
Latest quarterly updates
Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.
172
projects in our pipeline
14
new molecular entities in our late-stage pipeline
1
new molecular entity under review
Phase III/LCM Projects: refers to assets that are pivotal in Phase II/III, or that have been submitted for regulatory approval, and may include assets that are now launched in one or more major markets (removed when launched in all applicable major markets).
Oncology (as of 28 July 2023)
Phase I
Phase I
Phase II
Phase II
Phase III
Phase III
LCM Projects
LCM Projects
Cardiovascular, Renal and Metabolism (as of 28 July 2023)
Phase I
Phase I
Phase II
Phase II
Phase III
Phase III
LCM Projects
LCM Projects
Respiratory & Immunology (as of 28 July 2023)
Phase I
Phase I
Phase II
Phase III
Phase III
LCM Projects
LCM Projects
Rare Disease (as of 28 July 2023)
Phase I
Phase I
Phase II
Phase II
Phase III
Phase III
LCM Projects
LCM Projects
Vaccine & Immune therapies (as of 28 July 2023)
Phase I
Phase I
Phase II
Phase II
Phase III
Phase III
LCM Projects
LCM Projects
Other (as of 28 July 2023)
Phase I
Phase II
Phase II
Phase III
Phase III
LCM Projects
LCM Projects
Removed since last quarter
Veeva ID: Z4-57208
Date of preparation: August 2023